Characteristic | Overall Survival | Relapse-Free Survival | ||||
---|---|---|---|---|---|---|
HR | 95% CI | P value | HR | 95% CI | P value | |
 Gender | ||||||
  Male vs. Female | 0.225 | 0.053–0.950 | 0.042* | 0.247 | 0.075–0.819 | 0.022* |
 Age (y) | ||||||
   < 46 vs. ≥46 | 1.389 | 0.673–2.867 | 0.374 | 2.099 | 1.027–4.293 | 0.042* |
 Tumor size | ||||||
  T1 + T2 vs. T3 + T4 | 0.873 | 0.292–2.611 | 0.809 | 0.972 | 0.325–2.905 | 0.959 |
 Lymphoid nodal states | ||||||
  N0-1 vs. N2-3 | 2.312 | 0.969–5.519 | 0.050* | 2.662 | 1.146–6.187 | 0.023* |
 Clinical Stage | ||||||
  1 + 2 vs. 3 + 4 | 0.798 | 0.327–1.945 | 0.619 | 0.856 | 0.284–2.579 | 0.783 |
 Local-regional relapse | ||||||
  Yes vs. NO | 2.296 | 1.013–5.204 | 0.047* | 23.877 | 9.554–59.668 | 0.000* |
 Metastasis | ||||||
  Yes vs. No | 9.085 | 1.871–44.128 | 0.006* | 5.045 | 1.195–21.288 | 0.028* |
 WHO histological classification | ||||||
  NKUC vs. NKDC | 0.680 | 0.148–3.121 | 0.620 | 0.580 | 0.129–2.609 | 0.477 |
 EA | ||||||
   ≤ 1:10 vs. >1:10 | 0.568 | 0.234–1.381 | 0.212 | 0.679 | 0.275–1.677 | 0.401 |
 VCA | ||||||
   ≤ 1:40 vs. >1:40 | 0.613 | 0.207–1.816 | 0.377 | 0.376 | 0.131–1.084 | 0.070 |
 IGFBP-1 | ||||||
  Low vs. High | 0.802 | 0.330–1.947 | 0.626 | 0.520 | 0.213–1.267 | 0.150 |
 IGF-1 | ||||||
  Low vs. High | 1.649 | 0.612–4.443 | 0.323 | 1.450 | 0.602–3.490 | 0.407 |
 IGFBP-1/IGF-1 | ||||||
   > 1 vs. ≤1 | 0.298 | 0.096–0.920 | 0.035* | 0.334 | 0.115–0.969 | 0.044* |